Tibet Pharmaceuticals released its 2026 interim report, with net profit attributable to the parent company of 608 million yuan. The company's total operating revenue was 1.554 billion yuan, down 5.83 percent from the same period last year. Net cash inflow from operating activities was 479 million yuan, down 20.17 percent year on year. The company's latest asset-liability ratio was 34.41 percent, gross margin was 93.00 percent, and diluted earnings per share was 1.91 yuan.
Tibet Rhodiola Pharmaceutical Holding CoReports net profit of 608 million yuan, but revenue declined 5.83% and operating cash flow fell 20.17%.
Tibet Aim Pharm Inc